ZA200402285B - Ophthalmologic treatment methods using selective iNOS inhibitors. - Google Patents

Ophthalmologic treatment methods using selective iNOS inhibitors.

Info

Publication number
ZA200402285B
ZA200402285B ZA200402285A ZA200402285A ZA200402285B ZA 200402285 B ZA200402285 B ZA 200402285B ZA 200402285 A ZA200402285 A ZA 200402285A ZA 200402285 A ZA200402285 A ZA 200402285A ZA 200402285 B ZA200402285 B ZA 200402285B
Authority
ZA
South Africa
Prior art keywords
treatment methods
inos inhibitors
selective inos
ophthalmologic treatment
ophthalmologic
Prior art date
Application number
ZA200402285A
Other languages
English (en)
Inventor
Pamela T Manning
Jane R Connor
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ZA200402285B publication Critical patent/ZA200402285B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200402285A 2001-09-24 2004-03-23 Ophthalmologic treatment methods using selective iNOS inhibitors. ZA200402285B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/961,816 US20030109522A1 (en) 2001-09-24 2001-09-24 Ophthalmologic treatment methods using selective iNOS inhibitors

Publications (1)

Publication Number Publication Date
ZA200402285B true ZA200402285B (en) 2005-06-13

Family

ID=25505060

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200402285A ZA200402285B (en) 2001-09-24 2004-03-23 Ophthalmologic treatment methods using selective iNOS inhibitors.

Country Status (13)

Country Link
US (1) US20030109522A1 (enExample)
EP (1) EP1429777A4 (enExample)
JP (1) JP2005506986A (enExample)
KR (1) KR20040039393A (enExample)
CN (1) CN1556707A (enExample)
AU (1) AU2002327041A2 (enExample)
BR (1) BR0212991A (enExample)
CA (1) CA2455910A1 (enExample)
IL (1) IL161004A0 (enExample)
MX (1) MXPA04002711A (enExample)
PL (1) PL369338A1 (enExample)
WO (1) WO2003026668A1 (enExample)
ZA (1) ZA200402285B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090088472A1 (en) * 2005-05-17 2009-04-02 Kouji Oohashi Protective Agent for Neuronal Cell Comprising Amidino Derivative as Active Ingredient
AU2016396401B2 (en) 2016-03-07 2023-07-13 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132453A (en) * 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
US5830917A (en) * 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) * 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
GB9811599D0 (en) * 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6586474B2 (en) * 2000-03-24 2003-07-01 Pharmacia Corporation Amidino compounds useful as nitric oxide synthase inhibitors
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Also Published As

Publication number Publication date
JP2005506986A (ja) 2005-03-10
US20030109522A1 (en) 2003-06-12
WO2003026668A1 (en) 2003-04-03
EP1429777A4 (en) 2005-06-22
AU2002327041A2 (en) 2003-04-07
PL369338A1 (en) 2005-04-18
CN1556707A (zh) 2004-12-22
EP1429777A1 (en) 2004-06-23
MXPA04002711A (es) 2004-07-05
IL161004A0 (en) 2004-08-31
KR20040039393A (ko) 2004-05-10
CA2455910A1 (en) 2003-04-03
BR0212991A (pt) 2004-08-17

Similar Documents

Publication Publication Date Title
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
GB0112343D0 (en) Well treatment
AP2210A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
AU2002215125A1 (en) Well treatment method
IL160754A0 (en) Dosage form, device and methods of treatment
GB0129976D0 (en) Treatment method
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL161005A0 (en) Neuroprotective treatment methods using selective inos inhibitors
MXPA03006249A (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
GB0120147D0 (en) Treatment method
HUP0303303A3 (en) Treatment bed, treatment apparatus and treatment device
GB0130763D0 (en) Treatment methods
SG89379A1 (en) Treatment apparatus
GB0026838D0 (en) Treatment method
IL161004A0 (en) Ophthalmologic treatment methods using selective inos inhibitors
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
GB0031321D0 (en) Treatment
GB0126253D0 (en) Treatment method
ITGE20010007U4 (it) Apparato per trattamenti fisiologici.
HK1068248A (en) Neuroprotective treatment methods using selective inos inhibitors
GB0130694D0 (en) Treatment
ZA200304439B (en) Therapeutic treatment.
GB0102927D0 (en) Treatment method
GB0110191D0 (en) Sterilization method
ZA200205839B (en) Methods for the treatment of substance abuse.